Difference between revisions of "DSC MRI Biomarker Ctte"
| Line 6: | Line 6: | ||
==Project Snapshot== | ==Project Snapshot== | ||
| − | Develop a quantitative imaging profile for Dynamic Susceptibility Contrast MRI. | + | Develop a quantitative imaging profile for Dynamic Susceptibility Contrast MRI. |
| − | + | <br/> | |
| − | + | This QIBA Profile, Dynamic-Susceptibility-Contrast Magnetic Resonance Imaging (DSC-MRI), released 2020-10-20, addresses the measurement of an imaging biomarker for relative Cerebral Blood Volume (rCBV) for the evaluation of brain tumor progression or response to therapy. We note here, that this profile does not claim to be measuring quantitative rCBV due to lack of existing supporting literature; it does provide claims for a biomarker that is proportional to rCBV, which is the tissue-normalized area under the contrast-agent concentration curve (AUC-TN). The AUC-TN therefore has merit as a potential biomarker for diseases or treatments that impact rCBV. This profile places requirements on Sites, Acquisition Devices, Contrast Injectors, Contrast Media, Radiologists, Physicists, Technologists, Reconstruction Software, Image Analysis Tools and Image Analysts involved in Site Conformance, Staff Qualification, Product Validation, Pre-delivery, Periodic QA, Protocol Design, Subject Handling, Image Data Acquisition, Image Data Reconstruction, Image QA, Image Distribution, Image Analysis and Image Interpretation. The requirements are focused on achieving known (ideally negligible) bias and avoiding unnecessary variability of the of the AUC-TN measurements. | |
| + | <br/> | ||
| + | This profile is intended to help clinicians basing decisions on this biomarker, imaging staff generating this biomarker, vendor staff developing related products, purchasers of such products and investigators designing trials with imaging endpoints. | ||
| + | <br/> | ||
| + | Note that this profile only states requirements to achieve the claim, '''not''' “requirements on standard of care.” Conformance to this Profile is secondary to properly caring for the patient. | ||
==DSC MRI Meetings== | ==DSC MRI Meetings== | ||
Revision as of 23:38, 6 November 2020
- Co-chairs: Bradley Erickson, MD, PhD; Ona Wu, PhD
- RSNA Staff Support: Susan Stanfa
Project Snapshot
Develop a quantitative imaging profile for Dynamic Susceptibility Contrast MRI.
This QIBA Profile, Dynamic-Susceptibility-Contrast Magnetic Resonance Imaging (DSC-MRI), released 2020-10-20, addresses the measurement of an imaging biomarker for relative Cerebral Blood Volume (rCBV) for the evaluation of brain tumor progression or response to therapy. We note here, that this profile does not claim to be measuring quantitative rCBV due to lack of existing supporting literature; it does provide claims for a biomarker that is proportional to rCBV, which is the tissue-normalized area under the contrast-agent concentration curve (AUC-TN). The AUC-TN therefore has merit as a potential biomarker for diseases or treatments that impact rCBV. This profile places requirements on Sites, Acquisition Devices, Contrast Injectors, Contrast Media, Radiologists, Physicists, Technologists, Reconstruction Software, Image Analysis Tools and Image Analysts involved in Site Conformance, Staff Qualification, Product Validation, Pre-delivery, Periodic QA, Protocol Design, Subject Handling, Image Data Acquisition, Image Data Reconstruction, Image QA, Image Distribution, Image Analysis and Image Interpretation. The requirements are focused on achieving known (ideally negligible) bias and avoiding unnecessary variability of the of the AUC-TN measurements.
This profile is intended to help clinicians basing decisions on this biomarker, imaging staff generating this biomarker, vendor staff developing related products, purchasers of such products and investigators designing trials with imaging endpoints.
Note that this profile only states requirements to achieve the claim, not “requirements on standard of care.” Conformance to this Profile is secondary to properly caring for the patient.
DSC MRI Meetings
Recent Approved call summaries:
Note: The last meeting of this group was held on October 14, 2020; notes are posted after they are approved by the DSC-MRI BC during the following t-con
DSC-MRI Call Summaries Archive
- Earlier materials can be found on the PDF-MRI (Perfusion, Diffusion and Flow) Biomarker Committee page
Profile Development
- DSC Profile Stage 1 Version for Public Comment (comments closed on May 15, 2020)
- DSC Profile Stage 2 Consensus Profile (released 2020-10-22)
Historical Background - Formation of the Group
Reference Materials
QIBA Funded Projects
Round 5
- Original Proposal to the QIBA Steering Committee